Lee S Schwartzberg1, Stanley M Marks2, Nashat Y Gabrail3, Robert B Geller4, Jonathan Kish5. 1. Division of Hematology/Oncology, Department of Medicine, University of Tennessee Health Sciences Center and West Cancer Center, 7945 Wolf River Blvd, Germantown, TN 38138, USA. 2. Division of Medical Hematology/Oncology, UPMC Hillman Cancer Center, 5150 Centre Ave, 5th Floor, Cancer Pavilion, Pittsburgh, PA 15232, USA. 3. Department of Oncology, Gabrail Cancer Center, 4875 Higbee Ave NW, Canton, OH 44718, USA. 4. Medical Affairs, Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA. 5. Real World Evidence and Insights, Cardinal Health Specialty Solutions, 7000 Cardinal Place, 4th Floor, Columbus, OH 43017, USA.
Abstract
Aim: To evaluate real-world effectiveness of guideline-recommended palonosetron-containing antiemetic regimens in patients receiving highly (HEC) or moderately emetogenic (MEC) chemotherapy. Patients & methods: This retrospective analysis used records of adults receiving first-line chemotherapy and a three-drug palonosetron-containing antiemetic regimen for HEC or palonosetron-containing antiemetic regimen for MEC (carboplatin). Results: A total of 1587 records were evaluated. For HEC and MEC, respectively, chemotherapy-induced nausea and vomiting (CINV) occurred in 40 versus 44% of patient cycles (p = 0.01), and unscheduled iv. antiemetics in 41 versus 35% (p < 0.05). A total of 48% of HEC patients versus 42% of MEC patients had CINV-related clinic visits (p = 0.05). Conclusion: Palonosetron-containing antiemetic regimens may provide insufficient CINV control. Alternative regimens may improve patient quality of life and reduce healthcare resource utilization.
Aim: To evaluate real-world effectiveness of guideline-recommended palonosetron-containing antiemetic regimens in patients receiving highly (HEC) or moderately emetogenic (MEC) chemotherapy. Patients & methods: This retrospective analysis used records of adults receiving first-line chemotherapy and a three-drug palonosetron-containing antiemetic regimen for HEC or palonosetron-containing antiemetic regimen for MEC (carboplatin). Results: A total of 1587 records were evaluated. For HEC and MEC, respectively, chemotherapy-induced nausea and vomiting (CINV) occurred in 40 versus 44% of patient cycles (p = 0.01), and unscheduled iv. antiemetics in 41 versus 35% (p < 0.05). A total of 48% of HECpatients versus 42% of MEC patients had CINV-related clinic visits (p = 0.05). Conclusion:Palonosetron-containing antiemetic regimens may provide insufficient CINV control. Alternative regimens may improve patient quality of life and reduce healthcare resource utilization.
Entities:
Keywords:
chemotherapy-induced nausea and vomiting; granisetron extended-release sc.; palonosetron
Authors: Matti Aapro; Florian Scotté; Yolanda Escobar; Luigi Celio; Richard Berman; Alessandra Franceschetti; Danielle Bell; Karin Jordan Journal: Oncologist Date: 2021-03-17